Immunization after hematopoietic stem cell transplantation

From IDWiki
Revision as of 02:35, 28 February 2020 by Aidan (talk | contribs) (Text replacement - "Category:Immunocompromised patients" to "Category:Immunocompromised hosts")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
  • After autologous or allogeneic hematopoietic stem cell transplantation, patients need essentially all vaccines repeated

Guidelines

  • DTaP-HiB-IPV: 6 to 12 months after transplant
  • Hepatitis B: 6 to 12 months after transplant
    • Doses at 0, 1, and 6 months using high dose (40 μg)
    • Monitor HBsAb titres annually
  • Influenza: annually
  • Pneumococcal C-13 (Prevnar): 3 to 6 months after transplant
    • 3 doses 4 weeks apart
  • Pneumococcal P-23 (Pneumovax): 6 to 12 months after last dose of C-13
    • 1 dose with a booster after 12 months
    • If GVHD, give an extra dose of C-13 and delay P-23 until GVHD resolved
  • Meningococcal conjugate (quadrivalent): 6 months
    • 1 dose
    • If given before 6 months, will need another after 6 months and at least 2 months after the first
  • Live vaccines (varicella, MMR, and yellow fever) at least 24 months after transplant, as long as no chronic GVHD, immunosuppression has been stopped for at least 3 months, and no active underlying disease
    • If receiving IVIg, delay MMR and varicella vaccines until 8 to 11 months after last dose
    • Check titres after second dose of MMR or varicella
  • Contraindicated:

Sample Schedule

Immunization Comments Time post-transplant (months)
6 7 8 10 12 14 18 24
DTaP Hib IPV (Pediacel) Diptheria, tetanus, pertussis, polio, and Haemophilus influenzae type b X X X X
Hepatitis B High-dose vaccine; monitor HBsAb titres annually X X X
Pneumococcal C-13 (Prevnar) X X X
Pneumococcal P-23 (Pneumovax) X
Meningococcal conjugate (Menactra) X X
Influenza (inactivated) Annually
Varicella Only given if no titres at 24 months. Give extra dose 3 months later if no seroconversion. X
MMR Only given if no titres at 24 months. Give extra dose 3 months later if no seroconversion. X
HPV Ages 9 to 26 years, and possibly older X X X
Herpes zoster recombinant inactivated (Shingrix) Two doses at least one month apart
Hepatitis A If risks present or travel planned X X
Cholera/traveller's diarrhea (inactivated) If indicated at least 6 months
Typhoid (inactivated) If indicated at least 6 months
Japanese encephalitis If indicated at least 6 months
Meningococcal B If indicated by risk factors such as funtional hyposplenia at least 6 months
Rabies If indicated at least 6 months

Further Reading